202 related articles for article (PubMed ID: 28744737)
1. Neuroendocrine Liver Metastasis: Prognostic Implications of Primary Tumor Site on Patients Undergoing Curative Intent Liver Surgery.
Spolverato G; Bagante F; Aldrighetti L; Poultsides G; Bauer TW; Field RC; Marques HP; Weiss M; Maithel SK; Pawlik TM
J Gastrointest Surg; 2017 Dec; 21(12):2039-2047. PubMed ID: 28744737
[TBL] [Abstract][Full Text] [Related]
2. Hepatic Resection for Non-functional Neuroendocrine Liver Metastasis: Does the Presence of Unresected Primary Tumor or Extrahepatic Metastatic Disease Matter?
Xiang JX; Zhang XF; Beal EW; Weiss M; Aldrighetti L; Poultsides GA; Bauer TW; Fields RC; Maithel SK; Marques HP; Pawlik TM
Ann Surg Oncol; 2018 Dec; 25(13):3928-3935. PubMed ID: 30218247
[TBL] [Abstract][Full Text] [Related]
3. Early Recurrence of Neuroendocrine Liver Metastasis After Curative Hepatectomy: Risk Factors, Prognosis, and Treatment.
Zhang XF; Beal EW; Chakedis J; Lv Y; Bagante F; Aldrighetti L; Poultsides GA; Bauer TW; Fields RC; Maithel SK; Marques HP; Weiss M; Pawlik TM
J Gastrointest Surg; 2017 Nov; 21(11):1821-1830. PubMed ID: 28730354
[TBL] [Abstract][Full Text] [Related]
4. The Impact of Extent of Liver Resection Among Patients with Neuroendocrine Liver Metastasis: an International Multi-institutional Study.
Sham JG; Ejaz A; Gage MM; Bagante F; Reames BN; Maithel S; Poultsides GA; Bauer TW; Fields RC; Weiss MJ; Marques HP; Aldrighetti L; Pawlik TM; He J
J Gastrointest Surg; 2019 Mar; 23(3):484-491. PubMed ID: 29980977
[TBL] [Abstract][Full Text] [Related]
5. Early recurrence of well-differentiated (G1) neuroendocrine liver metastasis after curative-intent surgery: Risk factors and outcome.
Xiang JX; Zhang XF; Weiss M; Aldrighetti L; Poultsides GA; Bauer TW; Fields RC; Maithel SK; Marques HP; Pawlik TM
J Surg Oncol; 2018 Dec; 118(7):1096-1104. PubMed ID: 30261105
[TBL] [Abstract][Full Text] [Related]
6. Neuroendocrine liver metastasis: The chance to be cured after liver surgery.
Bagante F; Spolverato G; Merath K; Postlewait LM; Poultsides GA; Mullen MG; Bauer TW; Fields RC; Lamelas J; Marques HP; Aldrighetti L; Tran T; Maithel SK; Pawlik TM
J Surg Oncol; 2017 May; 115(6):687-695. PubMed ID: 28146608
[TBL] [Abstract][Full Text] [Related]
7. Timing of disease occurrence and hepatic resection on long-term outcome of patients with neuroendocrine liver metastasis.
Zhang XF; Beal EW; Weiss M; Aldrighetti L; Poultsides GA; Bauer TW; Fields RC; Maithel SK; Marques HP; Pawlik TM
J Surg Oncol; 2018 Feb; 117(2):171-181. PubMed ID: 28940257
[TBL] [Abstract][Full Text] [Related]
8. Liver Resection for Neuroendocrine Tumor Liver Metastases Within Milan Criteria for Liver Transplantation.
Ruzzenente A; Bagante F; Bertuzzo F; Aldrighetti L; Campagnaro T; Ercolani G; Conci S; Giuliante F; Dore A; Ferrero A; Torzilli G; Grazi GL; Ratti F; Cucchetti A; De Rose AM; Russolillo N; Cimino M; Perri P; Guglielmi A; Iacono C
J Gastrointest Surg; 2019 Jan; 23(1):93-100. PubMed ID: 30242647
[TBL] [Abstract][Full Text] [Related]
9. The impact of extrahepatic disease among patients undergoing liver-directed therapy for neuroendocrine liver metastasis.
Ejaz A; Reames BN; Maithel S; Poultsides GA; Bauer TW; Fields RC; Weiss M; Marques HP; Aldrighetti L; Pawlik TM
J Surg Oncol; 2017 Dec; 116(7):841-847. PubMed ID: 28650564
[TBL] [Abstract][Full Text] [Related]
10. Surgical resection of neuroendocrine tumor liver metastases as part of multimodal treatment strategies: A propensity score matching analysis.
Schreckenbach T; Hübert H; Koch C; Bojunga J; Schnitzbauer AA; Bechstein WO; Holzer K
Eur J Surg Oncol; 2019 May; 45(5):808-815. PubMed ID: 30611565
[TBL] [Abstract][Full Text] [Related]
11. Outcomes of Cytoreductive Surgery for Metastatic Low-Grade Neuroendocrine Tumors in the Setting of Extrahepatic Metastases.
Chan DL; Dixon M; Law CHL; Koujanian S; Beyfuss KA; Singh S; Myrehaug S; Hallet J
Ann Surg Oncol; 2018 Jun; 25(6):1768-1774. PubMed ID: 29560571
[TBL] [Abstract][Full Text] [Related]
12. Management and outcomes of patients with recurrent neuroendocrine liver metastasis after curative surgery: An international multi-institutional analysis.
Spolverato G; Bagante F; Aldrighetti L; Poultsides GA; Bauer TW; Fields RC; Maithel SK; Marques HP; Weiss M; Pawlik TM
J Surg Oncol; 2017 Sep; 116(3):298-306. PubMed ID: 28513896
[TBL] [Abstract][Full Text] [Related]
13. Alternative lengthening of telomeres predicts site of origin in neuroendocrine tumor liver metastases.
Dogeas E; Karagkounis G; Heaphy CM; Hirose K; Pawlik TM; Wolfgang CL; Meeker A; Hruban RH; Cameron JL; Choti MA
J Am Coll Surg; 2014 Apr; 218(4):628-35. PubMed ID: 24655849
[TBL] [Abstract][Full Text] [Related]
14. Outcomes of laparoscopic tumor ablation for neuroendocrine liver metastases: a 20-year experience.
Kose E; Kahramangil B; Aydin H; Donmez M; Takahashi H; Aucejo F; Siperstein A; Berber E
Surg Endosc; 2020 Jan; 34(1):249-256. PubMed ID: 30945061
[TBL] [Abstract][Full Text] [Related]
15. Conditional disease-free survival after curative-intent liver resection for neuroendocrine liver metastasis.
Sahara K; Merath K; Tsilimigras DI; Hyer JM; Guglielmi A; Aldrighetti L; Weiss M; Fields RC; Poultsides GA; Maithel SK; Endo I; Pawlik TM; Other Members Of The U S Neuroendocrine Tumor Study Group
J Surg Oncol; 2019 Dec; 120(7):1087-1095. PubMed ID: 31550406
[TBL] [Abstract][Full Text] [Related]
16. Cytoreductive debulking surgery among patients with neuroendocrine liver metastasis: a multi-institutional analysis.
Ejaz A; Reames BN; Maithel S; Poultsides GA; Bauer TW; Fields RC; Weiss MJ; Marques HP; Aldrighetti L; Pawlik TM
HPB (Oxford); 2018 Mar; 20(3):277-284. PubMed ID: 28964630
[TBL] [Abstract][Full Text] [Related]
17. Assessing the role of primary tumour resection in patients with synchronous unresectable liver metastases from pancreatic neuroendocrine tumour of the body and tail. A propensity score survival evaluation.
Bertani E; Fazio N; Radice D; Zardini C; Spinoglio G; Chiappa A; Ribero D; Biffi R; Partelli S; Falconi M
Eur J Surg Oncol; 2017 Feb; 43(2):372-379. PubMed ID: 27742480
[TBL] [Abstract][Full Text] [Related]
18. Surgery versus intra-arterial therapy for neuroendocrine liver metastasis: a multicenter international analysis.
Mayo SC; de Jong MC; Bloomston M; Pulitano C; Clary BM; Reddy SK; Clark Gamblin T; Celinski SA; Kooby DA; Staley CA; Stokes JB; Chu CK; Arrese D; Ferrero A; Schulick RD; Choti MA; Geschwind JF; Strub J; Bauer TW; Adams RB; Aldrighetti L; Mentha G; Capussotti L; Pawlik TM
Ann Surg Oncol; 2011 Dec; 18(13):3657-65. PubMed ID: 21681380
[TBL] [Abstract][Full Text] [Related]
19. Surgery Provides Long-Term Survival in Patients with Metastatic Neuroendocrine Tumors Undergoing Resection for Non-Hormonal Symptoms.
Chakedis J; Beal EW; Lopez-Aguiar AG; Poultsides G; Makris E; Rocha FG; Kanji Z; Weber S; Fisher A; Fields R; Krasnick BA; Idrees K; Marincola-Smith P; Cho C; Beems M; Pawlik TM; Maithel SK; Schmidt CR; Dillhoff M
J Gastrointest Surg; 2019 Jan; 23(1):122-134. PubMed ID: 30334178
[TBL] [Abstract][Full Text] [Related]
20. Survival prognostic factors of gastro-enteric-pancreatic neuroendocrine tumors after primary tumor resection in a single tertiary center: Comparison of gastro-enteric and pancreatic locations.
Russolillo N; Vigano' L; Razzore P; Langella S; Motta M; Bertuzzo F; Papotti M; Ferrero A
Eur J Surg Oncol; 2015 Jun; 41(6):751-7. PubMed ID: 25887286
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
